Point72 Europe (London) LLP Annexon, Inc. Transaction History
Point72 Europe (London) LLP
- $1.48 Billion
- Q3 2024
A detailed history of Point72 Europe (London) LLP transactions in Annexon, Inc. stock. As of the latest transaction made, Point72 Europe (London) LLP holds 159,953 shares of ANNX stock, worth $825,357. This represents 0.06% of its overall portfolio holdings.
Number of Shares
159,953
Previous 234,592
31.82%
Holding current value
$825,357
Previous $1.15 Million
17.67%
% of portfolio
0.06%
Previous 0.1%
Shares
2 transactions
Others Institutions Holding ANNX
# of Institutions
146Shares Held
102MCall Options Held
178KPut Options Held
159K-
Bain Capital Life Sciences Investors, LLC Boston, MA8.45MShares$43.6 Million8.98% of portfolio
-
Satter Management Co., L.P.7.41MShares$38.2 Million76.44% of portfolio
-
Bvf Inc San Francisco, CA7MShares$36.1 Million1.32% of portfolio
-
Black Rock Inc. New York, NY6.59MShares$34 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA6.43MShares$33.2 Million2.49% of portfolio
About Annexon, Inc.
- Ticker ANNX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,617,700
- Market Cap $246M
- Description
- Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapeutics for autoimmune, neurodegenerative, and ophthalmic disorders. The company's C1q is an initiating molecule of the classical complement pathway that targets distinct disease processes, such as antibody-mediated autoimmune disease and complement-mediated n...